Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic pathways and preclinical animal studies without systematic methodology
PubMed 26856717 · doi:10.1007/s10620-016-4054-0
What was done
This paper reviewed the mechanistic pathways linking dietary fructose consumption, hepatic de novo lipogenesis (DNL), and nonalcoholic fatty liver disease (NAFLD), integrating evidence from cellular biochemistry, human metabolic studies, and rodent knockout models.
What was found
The abstract reports no numerical data or effect estimates. It reports that hepatic DNL is elevated in individuals with NAFLD while dietary fat and plasma free fatty acid contributions remain relatively unchanged. Fructose is delivered to the liver at high concentrations via the portal vein, upregulates DNL enzymes more strongly than high-fat diets, stimulates SREBP1c without requiring insulin, depletes ATP, inhibits mitochondrial fatty acid oxidation, increases reactive oxygen species, and promotes endoplasmic reticulum stress and uric acid formation.
Why it matters
It synthesizes the distinct biochemical properties that make fructose exceptionally lipogenic, highlighting the fructose metabolic pathway as a potential therapeutic target in NAFLD management.
Limits
As a narrative review, it lacks systematic search criteria, quality assessment of included studies, and quantitative meta-analytic pooling. Many of the cited mechanisms rely on rodent knockout models and in vitro pathways that may not fully reflect human clinical outcomes.
Cited by
- supports High-fructose corn syrup simultaneously stimulates fat accumulation and blocks fat burning in the liver.